Biofrontera starts patient recruitment for U.S. Phase III Trial Evaluating Ameluz® / BF-RhodoLED® for Superficial Basal Cell Carcinoma

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs
Biofrontera AG announces mediation results
Biofrontera AG announces initiation of clinical studies
Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021
Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp
Biofrontera reports preliminary approximate revenues for the month of September 2021
Biofrontera reports preliminary revenue for the month of August 2021
Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.